NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $3.66 -0.06 (-1.61%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$3.59 -0.07 (-1.91%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Opus Genetics alerts:Sign Up Key Stats Today's Range$3.53▼$3.7550-Day Range$2.92▼$4.6452-Week Range$1.04▼$5.81Volume915,127 shsAverage Volume907,318 shsMarket Capitalization$302.21 millionP/E RatioN/ADividend YieldN/APrice Target$10.69Consensus RatingModerate Buy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 58% of companies evaluated by MarketBeat, and ranked 382nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingOpus Genetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 15 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialOpus Genetics has a consensus price target of $10.69, representing about 192.1% upside from its current price of $3.66.Amount of Analyst CoverageOpus Genetics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.10) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 16.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.08% of the float of Opus Genetics has been sold short.Short Interest Ratio / Days to CoverOpus Genetics has a short interest ratio ("days to cover") of 12.52, which indicates bearish sentiment.Change versus previous monthShort interest in Opus Genetics has recently increased by 24.76%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.29 News SentimentOpus Genetics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Opus Genetics this week, compared to 5 articles on an average week.Search Interest3 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Opus Genetics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,481,629.00 in company stock.Percentage Held by Insiders11.70% of the stock of Opus Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRD Stock News HeadlinesOpus Genetics (NASDAQ:IRD) Stock Rating Upgraded by Wall Street ZenAugust 8 at 2:01 AM | americanbankingnews.comOpus Genetics Inc.August 6 at 11:45 PM | barrons.comSpaceX Earnings Crash: The End of the AI Bubble?Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. SpaceX's latest earnings disappointed, and Morgan Stanley and Goldman Sachs now warn of a much bigger crisis unfolding over the next decade. TradeSmith CEO Keith Kaplan says there's another side to the AI story most people aren't discussing.August 8 at 1:00 AM | TradeSmith (Ad)Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateAugust 6 at 11:45 PM | finance.yahoo.comOpus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness DisorderAugust 4, 2026 | finance.yahoo.comOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseAugust 3, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)July 31, 2026 | theglobeandmail.comOpus Genetics (NASDAQ:IRD) COO Sells $13,653.36 in StockJuly 29, 2026 | insidertrades.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $2.01 at the beginning of the year. Since then, IRD stock has increased by 82.1% and is now trading at $3.66. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) issued its earnings results on Thursday, August, 6th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. Opus Genetics had a negative trailing twelve-month return on equity of 338.88% and a negative net margin of 1,091.82%. Who are Opus Genetics' major shareholders? Top institutional investors of Opus Genetics include BlackRock Inc. (3.77%), Texas Capital Bank Wealth Management Services Inc (0.15%), Bank of New York Mellon Corp (0.15%) and Deutsche Bank AG (0.06%). Insiders that own company stock include Fighting Blindness Foundation, Cam Gallagher, Cam Gallagher, George Magrath, Benjamin R Yerxa, Benjamin R Yerxa, Robert E Gagnon, Ashwath Jayagopal, Joseph K Schachle and Rabourn Amy Zaremba. View institutional ownership trends. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2026Today8/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 8 days, IRD's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year Founded2018Price Target and Rating Average Price Target for Opus Genetics$10.69 High Price Target$16.00 Low Price Target$7.00 Potential Upside/Downside+192.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.59 million Net Margins-1,091.82% Pretax Margin-892.36% Return on Equity-338.88% Return on Assets-180.94% Debt Debt-to-Equity RatioN/A Current Ratio7.13 Quick Ratio7.13 Sales & Book Value Annual Sales$14.20 million Price / Sales21.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book16.64Miscellaneous Outstanding Shares82,570,000Free Float72,906,000Market Cap$302.21 million OptionableN/A Beta0.59 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:IRD) was last updated on 8/8/2026 by MarketBeat.com Staff. From Our PartnersSpaceX Earnings Crash: The End of the AI Bubble?Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. ...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredWhy Trump really wants GreenlandThe petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then,...Porter & Company | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
